Printer Friendly

Articles from M2 Pharma (September 24, 2019)

1-27 out of 27 article(s)
Title Author Type Words
Acadia Pharmaceuticals Eyes USD 250m Raise from Stock Offering. 204
Active Biotech to present new data on laquinimod from the phase 2 LEGATO-HD study at the International congress of Parkinson's disease and movement disorders. 233
Ashford names Balaji Krishnamurthy as Pure Wellness' CEO. 278
AstraZeneca's Qtrilmet recommended for approval in EU by CHMP for type 2 diabetes. 243
Biodesix Highlights New Clinical Data Demonstrating VeriStrat Testing Predicts Survival in Advanced NSCLC and Immunotherapy. Clinical report 605
Bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D Gene Therapy for Cerebral Adrenoleukodystrophy at the 13th European Pediatric Neurology Society Congress. Clinical report 702
Cologuard wins FDA approval for Cologuard colorectal cancer screening test in younger individuals ages 45 to 49. 292
Detailed Imeglimin Phase 3 TIMES 1 Results Presented at 55th annual meeting of the European Association for the Study of Diabetes. 363
European Medicines Agency's committee provides positive opinion recommending approval of BAVENCIO. 162
FDA Grants Breakthrough Therapy Designation for Genentech's Gazyva in Lupus Nephritis. 688
FogPharma names new vice president of biology and new vice president and lead IP counsel. 256
Guerbet signs second agreement with IBM Watson Health to develop and market software solution to help diagnose prostate cancer. 239
Ironwood Pharmaceuticals, AstraZeneca Amend China Linzess Collaboration. 119
National Jewish Health partners with Self Care Catalysts Partner to advance respiratory care. 226
Onxeo Touts Positive Intermediate Results from the First Part of the DRIIV-1b Study Evaluating AsiDNA in Combination with Chemotherapy. 751
Phase I Study Results Show First-in-class NBTXR3 Could Present as a Valuable Option for Patients with Hepatocellular Carcinoma or Liver Metastasis. Report 881
Phoenix Molecular awarded FDA clearance to launch Phase 1/1b clinical trial of PMD-026 in advanced breast cancer. 225
Proton Therapy Partners names new board members. 259
Reneo Pharmaceuticals's REN001 granted Orphan Drug Designation by US FDA. 210
SanBio Granted Regenerative Medicine Advanced Therapy Designation from the US FDA for SB623 for the Treatment of Chronic Neurological Motor Deficits Secondary to Traumatic Brain Injury. Clinical report 634
Sarin to Become CFO at Alexion Pharmaceuticals. 298
Themis Raises EUR 40m in Series D Financing Round Backed by US/EU Consortium to Support Pivotal Study and Expand Clinical Pipeline. 616
University of California Office strengthens its CRISPR-Cas9 position in the US with new patent. 224
US FDA approves Merck's HIV-1 drugs Pifeltro and Delstrigo. 201
VBI Vaccines Launches Stock Offering. 373
Versantis Closes CHF 16M series B Financing Round to Advance Clinical Development of Novel Therapeutics for Liver Diseases. 564
Zilucoplan Selected as One of the First Therapeutic Candidates to be Tested in ALS Platform Trial. 402

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters